PwC consent added to S-1 amendment — Jade Biosciences (NASDAQ: JBIO)

Rhea-AI Filing Summary

Jade Biosciences, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 to furnish the consent of PricewaterhouseCoopers LLP dated March 6, 2026. The consent relates to PwC's report on the financial statements in the Form 10-K for the year ended December 31, 2025 and the Prospectus Supplement No. 1 dated March 6, 2026. The Amendment becomes effective upon filing under Rule 462(d).

As filed with the Securities and Exchange Commission on March 6, 2026

Registration No. 333-292369

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Post-Effective Amendment No. 1

TO

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

JADE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada		2836		83-137788
(State or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Code Number)		(I.R.S. Employer Identification No.)

221 Crescent St., Building 23

Suite 105

Waltham, MA 02453

(781) 312-3013

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive office)

Tom Frolich

Chief Executive Officer

Jade Biosciences, Inc.

221 Crescent St., Building 23

Suite 105

Waltham, MA 02453

(781) 312-3013

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Cheston Larson

Matt Bush

Anthony Gostanian

Latham & Watkins LLP

12670 High Bluff Drive

San Diego, California 92130

(858) 523-5400

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-292369)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging growth company		☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

This Post-Effective Amendment No. 1 shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(d) under the Securities Act of 1933, as amended.

EXPLANATORY NOTE

This Post-Effective Amendment No. 1 (this “Amendment”) to the Registration Statement on Form S-1 of Jade Biosciences, Inc. (File No. 333-292369), initially filed on December 22, 2025 and declared effective by the Securities and Exchange Commission on December 30, 2025 (the “Registration Statement”), is being filed as an exhibit-only filing solely to file the consent of PricewaterhouseCoopers LLP with respect to its report dated March 6, 2026 relating to the financial statements of Jade Biosciences, Inc. contained in its Annual Report on Form 10-K for the year ended December 31, 2025 and included in the Prospectus Supplement No. 1 dated March 6, 2026 filed pursuant to Rule 424(b)(3), filed herewith as Exhibit 23.1 (the “Consent”). Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, the signature pages to the Registration Statement and the Consent. The prospectus and the balance of Part II of the Registration Statement are unchanged hereby and have been omitted.

Part II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 16. Exhibits and Financial Statement Schedules.

(a) Exhibits.

Exhibit No.		Description
23.1*		Consent of PricewaterhouseCoopers LLP

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on March 6, 2026.

JADE BIOSCIENCES, INC.
By:		/s/ Bradford Dahms
Name:		Bradford Dahms
Title:		Chief Financial Officer and Treasurer

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature		Title		Date
/s/ Tom Frohlich		Chief Executive Officer & Director (Principal Executive Officer)		March 6, 2026
Tom Frohlich
/s/ Bradford Dahms		Chief Financial Officer and Treasurer		March 6, 2026
Bradford Dahms		(Principal Financial Officer and Principal Accounting Officer)
*		Chair of the Board		March 6, 2026
Eric Dobmeier, J.D.
*		Director		March 6, 2026
Chris Cain, Ph.D.
*		Director		March 6, 2026
Tomas Kiselak
*		Director		March 6, 2026
Lawrence Klein, Ph.D.
*		Director		March 6, 2026
Erin Lavelle

*		By:		/s/ Bradford Dahms
		Name:		Bradford Dahms
		Title:		Attorney-in-fact

FAQ

What does Jade Biosciences' Post-Effective Amendment No. 1 do (JBIO)?

It files PwC's consent dated March 6, 2026. The amendment adds the PricewaterhouseCoopers LLP consent to the Form S-1, referencing PwC's report on the financial statements in the Form 10-K for year ended December 31, 2025 and Prospectus Supplement No. 1.

Which PwC document is included in the amendment for JBIO?

The consent of PricewaterhouseCoopers LLP dated March 6, 2026. That consent pertains to PwC's report on Jade Biosciences' audited financial statements included in the company's Form 10-K for the year ended December 31, 2025.

Is the Form S-1 amendment effective immediately for JBIO?

Yes — it becomes effective upon filing under Rule 462(d). The filing states that Post-Effective Amendment No. 1 shall become effective upon filing with the SEC in accordance with Rule 462(d) under the Securities Act.

Does the amendment change the prospectus or other parts of the S-1 for JBIO?

No — the prospectus and the balance of Part II are unchanged. The Amendment states it consists only of the facing page, the explanatory note, Item 16 exhibits, signature pages, and the PwC consent; other sections were omitted because unchanged.